S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12

Opiant Pharmaceuticals Stock Forecast, Price & News

+0.67 (+2.95 %)
(As of 10/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume14,867 shs
Average Volume75,446 shs
Market Capitalization$102.87 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Opiant Pharmaceuticals logo

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$29.63 million
Book Value
$8.34 per share


Net Income
$-1.86 million




Market Cap
$102.87 million
Next Earnings Date
11/11/2021 (Confirmed)
Not Optionable

Social Links


Overall MarketRank

2.22 out of 5 stars

Medical Sector

337th out of 1,363 stocks

Pharmaceutical Preparations Industry

151st out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

Is Opiant Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Opiant Pharmaceuticals stock.
View analyst ratings for Opiant Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Opiant Pharmaceuticals?

Wall Street analysts have given Opiant Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Opiant Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Opiant Pharmaceuticals?

Opiant Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totaling 22,500 shares, an increase of 25.7% from the September 15th total of 17,900 shares. Based on an average daily trading volume, of 55,500 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.6% of the company's stock are short sold.
View Opiant Pharmaceuticals' Short Interest

When is Opiant Pharmaceuticals' next earnings date?

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Opiant Pharmaceuticals

How can I listen to Opiant Pharmaceuticals' earnings call?

Opiant Pharmaceuticals will be holding an earnings conference call on Thursday, November 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) released its quarterly earnings data on Thursday, August, 5th. The technology company reported $0.31 EPS for the quarter, beating the consensus estimate of ($0.28) by $0.59. The technology company earned $11.26 million during the quarter, compared to analyst estimates of $8.01 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 3.17% and a negative net margin of 3.06%.
View Opiant Pharmaceuticals' earnings history

How has Opiant Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OPNT stock has increased by 115.5% and is now trading at $23.38.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OPNT?

1 equities research analysts have issued 1-year price targets for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price.
View analysts' price targets for Opiant Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the following people:

What other stocks do shareholders of Opiant Pharmaceuticals own?

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $23.38.

How much money does Opiant Pharmaceuticals make?

Opiant Pharmaceuticals has a market capitalization of $102.87 million and generates $29.63 million in revenue each year. The technology company earns $-1.86 million in net income (profit) each year or ($0.44) on an earnings per share basis.

How many employees does Opiant Pharmaceuticals have?

Opiant Pharmaceuticals employs 31 workers across the globe.

When was Opiant Pharmaceuticals founded?

Opiant Pharmaceuticals was founded in 2009.

What is Opiant Pharmaceuticals' official website?

The official website for Opiant Pharmaceuticals is www.opiant.com.

Where are Opiant Pharmaceuticals' headquarters?

Opiant Pharmaceuticals is headquartered at 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at (310) 598-5410 or via email at [email protected].

This page was last updated on 10/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.